Treating Neurogenic Lower Urinary Tract Dysfunction in Chronic Spinal Cord Injury Patients-When Intravesical Botox Injection or Urethral Botox Injection Are Indicated.
Po-Cheng ChenKau-Han LeeWei-Chia LeeTing-Chun YehYuh-Chen KuoBing-Juin ChiangChun-Hou LiaoEn MengYao-Lin KaoYung-Chin LeeHann-Chorng KuoPublished in: Toxins (2023)
Lower urinary tract symptoms (LUTS), such as urgency, urinary incontinence, and/or difficulty voiding, hamper the quality of life (QoL) of patients with spinal cord injury (SCI). If not managed adequately, urological complications, such as urinary tract infection or renal function deterioration, may further deteriorate the patient's QoL. Botulinum toxin A (BoNT-A) injection within the detrusor muscle or urethral sphincter yields satisfactory therapeutic effects for treating urinary incontinence or facilitating efficient voiding; however, adverse effects inevitably follow its therapeutic efficacy. It is important to weigh the merits and demerits of BoNT-A injection for LUTS and provide an optimal management strategy for SCI patients. This paper summarizes different aspects of the application of BoNT-A injection for lower urinary tract dysfunctions in SCI patients and provides an overview of the benefits and drawbacks of this treatment.
Keyphrases
- spinal cord injury
- urinary incontinence
- end stage renal disease
- ejection fraction
- newly diagnosed
- chronic kidney disease
- urinary tract
- lower urinary tract symptoms
- spinal cord
- oxidative stress
- prognostic factors
- case report
- skeletal muscle
- benign prostatic hyperplasia
- neuropathic pain
- botulinum toxin
- patient reported